Novel tri-specific T-cell engager targeting IL-13Rα2 and EGFRvIII provides long-term survival in heterogeneous GBM challenge and promotes antitumor cytotoxicity with patient immune cells
Daniel H Park, Pratik S Bhojnagarwala, Kevin Liaw, Devivasha Bordoloi, Nicholas J Tursi, Shushu Zhao, Zev A Binder, Donald O’Rourke, David B Weiner · 2024
Read Novel tri-specific T-cell engager targeting IL-13Rα2 and EGFRvIII provides long-term survival in heterogeneous GBM challenge and promotes antitumor cytotoxicity with patient immune cells by Daniel H Park, Pratik S Bhojnagarwala, Kevin Liaw, Devivasha Bordoloi, Nicholas J Tursi, Shushu Zhao, Zev A Binder, Donald O’Rourke, David B Weiner (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11624777.txt.
Description
Daniel Park and eight colleagues build a three-way T-cell engager against brain tumor glioblastoma, in a twenty twenty-four study. The tumor varies its surface marks a lot, so single-target immune drugs often fail as cells escape. Their DNA-encoded engager grabs two tumor marks and the T cell at once. Three layouts were built and tested on cells carrying the marks.
All three bound well and drove strong killing in dishes. In mice with mixed tumors, the engager gave long survival. Patient immune cells also killed better after engager treatment. Gene reads showed which T-cell paths switched on. The authors see a way to beat tumor variety.
Catalog record
| CREATOR | Daniel H Park, Pratik S Bhojnagarwala, Kevin Liaw, Devivasha Bordoloi, Nicholas J Tursi, Shushu Zhao, Zev A Binder, Donald O’Rourke, David B Weiner |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 54 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |